Adenosine A_2A Receptor Agonist Polydeoxyribonucleotide Alleviates Interstitial Cystitis-Induced Voiding Dysfunction...

Area of Science:

• Pharmacology
• Urology
• Cell Biology

Background:

• Interstitial cystitis (IC) is a chronic bladder condition causing pain, frequency, and urgency.
• Current treatments for IC are limited, necessitating research into novel therapeutic agents.
• Polydeoxyribonucleotide (PDRN), an adenosine A2A receptor agonist, exhibits anti-inflammatory and anti-apoptotic properties.

Purpose of the Study:

• To investigate the therapeutic potential of PDRN in a cyclophosphamide-induced rat model of IC.
• To evaluate PDRN's effects on voiding dysfunction, bladder damage, and inflammatory markers in IC.

Main Methods:

• An IC animal model was established by administering cyclophosphamide intraperitoneally.
• Rats received daily intraperitoneal injections of PDRN (8 mg/kg) for 10 days post-IC induction.
• Voiding function, bladder edema, histological damage, pro-inflammatory cytokines, and apoptosis were assessed.

Main Results:

• Cyclophosphamide-induced IC resulted in voiding dysfunction, bladder edema, and histological damage.
• PDRN treatment significantly alleviated voiding dysfunction, bladder edema, and histological damage.
• PDRN suppressed the secretion of pro-inflammatory cytokines and reduced apoptosis in the bladder tissue.

Conclusions:

• PDRN demonstrates a therapeutic effect in an IC animal model.
• PDRN improves bladder function and promotes tissue repair by reducing inflammation and apoptosis.
• PDRN shows promise as an effective therapeutic agent for interstitial cystitis.